

From: [REDACTED]
Sent: Wednesday, 17 March 2021 2:55 PM
To: [REDACTED]
Subject: RE: Consultation paper - 2021-22 TGA fees and charges proposal [SEC=OFFICIAL]

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear [REDACTED]

I have now consulted amongst the ODMA membership and wider optical community to provide feedback on the consultation paper on TGA fees and charges.

The main companies to be affected by this are Equipment and Technology suppliers although frame and lens companies are still included because the decision to remove frames and ophthalmic lenses as Class 1 medical devices in late 2018 has still not been passed by the appropriate Regulation.

One of the issues raised by our group was that we don't know the operating expenses of the TGA and whether it is outside the normal range for business. It was noted that whilst applications for devices may increase by approximately \$15 each those for medicines would rise by \$1000-\$1500 if we support the preferred **Option 3 (Increase all fees and charges by indexation factor)**.

There are also concerns about the impact of the COVID-19 pandemic on the supply chain and increased pressure on business margins.


As such our combined response is **Option 1 – No increase in fees and charges**. A number of our members felt that if a projected \$6.2m loss might occur by choosing Option 1 then cost savings should be achieved from the TGA operating costs rather than an increase in fees.

Should you require any further information or wish to discuss this you can contact me by mobile on [REDACTED]

Kind Regards

Finola Carey
Chief Executive Officer
ODMA
PO Box 264
Terrey Hills NSW 2085

[REDACTED]
[REDACTED]
[REDACTED]



PRESENTED BY ODMA AND OPTOMETRY VICTORIA
AN INTERNATIONAL FIRST PROGRAMME FOR WEST AUSTRALIA, TASMANIA, PNG AND OVERSEAS

2-4 SEPTEMBER 2021
MELBOURNE, AUSTRALIA

opto21.com.au